The potential risk of neoadjuvant chemotherapy in breast cancer patients–results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).

Taucher S, Steger GG, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M Breast Cancer Res Treat. 2008 Nov,112(2):309-16. Epub 2007 Dec 14.

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R Breast Cancer Res Treat. 2008 Nov,112(1):203-13. Epub 2007 Dec 22.

A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.

Schmid P, KГјhnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, Freier W, KГјmmel S, Van de Velde H, Regierer A, Possinger K. Ann Oncol. 2008 May,19(5):871-6. doi: 10.1093/annonc/mdm569. Epub 2008 Jan 21.

Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.

Arkenau HT, Graeven U, Kubicka S, Grothey A, Englisch-Fritz C, Kretzschmar A, Greil R, Freier W, Seufferlein T, Hinke A, Schmoll HJ, Schmiegel W, Porschen R Clin Colorectal Cancer. 2008 Jan,7(1):60-4.

Tumour-immune cell interactions modulated by chemokines.

Jöhrer K, Pleyer L, Olivier A, Maizner E, Zelle-Rieser C, Greil R. Expert Opin Biol Ther. 2008 Mar,8(3):269-90. doi: 10.1517/14712598.8.3.269 .

Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.

Merkel O, Heyder C, Asslaber D, Hamacher F, Tinhofer I, Holler C, Stöcher M, Prokesch A, Papak C, Scheideler M, Trajanoski Z, Greil R. J Mol Med (Berl). 2008 May,86(5):541-52. doi: 10.1007/s00109-008-0314-6. Epub 2008 Feb 23.

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

Sonneveld P, Hajek R, Nagler A, Spencer A, BladГ© J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ Cancer. 2008 Apr 1,112(7):1529-37. doi: 10.1002/cncr.23326.

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.

von Moos R, Caspar CB, ThГјrlimann B, Angst R, Inauen R, Greil R, Bergstrom B, Schmieding K, Pecherstorfer M. Ann Oncol. 2008 Jul,19(7):1266-70. doi: 10.1093/annonc/mdn038. Epub 2008 Mar 11.

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M Clin Cancer Res. 2008 Mar 15,14(6):1767-74. doi: 10.1158/1078-0432.CCR-07-4122.

Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.

Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M Clin Cancer Res. 2008 Apr 1,14(7):2082-7. doi: 10.1158/1078-0432.CCR-07-2068.